Eli Lilly, Pfizer celebrate a PhIII success for their blockbuster pain drug contender tanezumab -- but questions linger
Five years after Eli Lilly stepped up with a $1.8 billion deal to bring Pfizer’s anti-NGF pain drug tanezumab back from limbo, the pharma giants …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
